Percutaneous left atrial appendage closure: beyond the classic indications

Enio E Guérios1, Francisco Chamié2

  • 1Department of Interventional Cardiology, Pilar Hospital, Curitiba, Brazil.

Asiaintervention
|March 20, 2023
PubMed

Insights

Percutaneous left atrial appendage closure (LAAC) offers an alternative to oral anticoagulation for stroke prevention in non-valvular atrial fibrillation. This review explores LAAC

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Medical Devices

Background:

  • Percutaneous left atrial appendage closure (LAAC) is an established stroke prevention strategy for non-valvular atrial fibrillation (NVAF).
  • Current guidelines recommend LAAC for NVAF patients with high thromboembolic risk and contraindications or high risk associated with oral anticoagulation (OAC).

Purpose of the Study:

  • To explore the expanded clinical utility of LAAC beyond traditional indications.
  • To discuss the potential benefits of LAAC in specific patient populations and clinical scenarios.

Main Methods:

  • Literature review and discussion of existing clinical evidence.
  • Analysis of LAAC application in various hemorrhagic diseases and specific patient groups.

Main Results:

  • LAAC may be beneficial in patients with specific hemorrhagic diseases, including cerebral amyloid angiopathy, age-related macular degeneration, hereditary hemorrhagic telangiectasia, and Moyamoya disease.
  • LAAC is also considered for patients post-left atrial appendage electrical isolation, with persistent LAA thrombus, in end-stage renal disease, and in those with anticipated poor OAC compliance.

Conclusions:

  • The role of LAAC in stroke prevention for NVAF is expanding.
  • LAAC presents a viable alternative in numerous clinical situations not currently covered by standard guidelines.